Literature DB >> 29566540

Molecular studies of CGRP and the CGRP family of peptides in the central nervous system.

Erica R Hendrikse1, Rebekah L Bower1, Debbie L Hay1,2, Christopher S Walker1.   

Abstract

BACKGROUND: Calcitonin gene-related peptide is an important target for migraine and other painful neurovascular conditions. Understanding the normal biological functions of calcitonin gene-related peptide is critical to understand the mechanisms of calcitonin gene-related peptide-blocking therapies as well as engineering improvements to these medications. Calcitonin gene-related peptide is closely related to other peptides in the calcitonin gene-related peptide family of peptides, including amylin. Relatedness in peptide sequence and in receptor biology makes it difficult to tease apart the contributions that each peptide and receptor makes to physiological processes and to disorders.
SUMMARY: The focus of this review is the expression of calcitonin gene-related peptide, related peptides and their receptors in the central nervous system. Calcitonin gene-related peptide is expressed throughout the nervous system, whereas amylin and adrenomedullin have only limited expression at discrete sites in the brain. The components of two receptors that respond to calcitonin gene-related peptide, the calcitonin gene-related peptide receptor (calcitonin receptor-like receptor with receptor activity-modifying protein 1) and the AMY1 receptor (calcitonin receptor with receptor activity-modifying protein 1), are expressed throughout the nervous system. Understanding expression of the peptides and their receptors lays the foundation for more deeply understanding their physiology, pathophysiology and therapeutic use.

Entities:  

Keywords:  Amylin; CGRP; adrenomedullin; calcitonin; central nervous system; migraine

Mesh:

Substances:

Year:  2018        PMID: 29566540     DOI: 10.1177/0333102418765787

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  14 in total

1.  Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting.

Authors:  Anne-Sophie Wattiez; Levi P Sowers; Andrew F Russo
Journal:  Expert Opin Ther Targets       Date:  2020-02-13       Impact factor: 6.902

2.  [Pathophysiological role of calcitonin gene-related peptide (CGRP) in migraine and cluster headache].

Authors:  Karl Meßlinger
Journal:  Schmerz       Date:  2020-04       Impact factor: 1.107

3.  Calcitonin receptor antibody validation and expression in the rodent brain.

Authors:  Erica R Hendrikse; Tayla A Rees; Zoe Tasma; Christelle Le Foll; Thomas A Lutz; Andrew Siow; Peter J Wookey; Christopher S Walker; Debbie L Hay
Journal:  Cephalalgia       Date:  2022-04-11       Impact factor: 6.075

4.  Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin.

Authors:  Rebekah L Bower; Lauren Yule; Tayla A Rees; Giuseppe Deganutti; Erica R Hendrikse; Paul W R Harris; Renata Kowalczyk; Zachary Ridgway; Amy G Wong; Katarzyna Swierkula; Daniel P Raleigh; Augen A Pioszak; Margaret A Brimble; Christopher A Reynolds; Christopher S Walker; Debbie L Hay
Journal:  ACS Pharmacol Transl Sci       Date:  2018-04-23

5.  Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients.

Authors:  Hashmat Ghanizada; Mohammad Al-Mahdi Al-Karagholi; Christopher S Walker; Nanna Arngrim; Tayla Rees; Jakeb Petersen; Andrew Siow; Mette Mørch-Rasmussen; Sheryl Tan; Simon J O'Carroll; Paul Harris; Lene Theil Skovgaard; Niklas Rye Jørgensen; Margaret Brimble; Jayme S Waite; Brandon J Rea; Levi P Sowers; Andrew F Russo; Debbie L Hay; Messoud Ashina
Journal:  Ann Neurol       Date:  2021-04-08       Impact factor: 11.274

6.  Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier.

Authors:  Rodrigo Noseda; Aaron J Schain; Agustin Melo-Carrillo; Jason Tien; Jennifer Stratton; Fanny Mai; Andrew M Strassman; Rami Burstein
Journal:  Cephalalgia       Date:  2019-12-19       Impact factor: 6.292

7.  Development of chimeric and bifunctional antagonists for CLR/RAMP receptors.

Authors:  Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

Review 8.  Beyond CGRP: The calcitonin peptide family as targets for migraine and pain.

Authors:  Tayla A Rees; Erica R Hendrikse; Debbie L Hay; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2021-07-27       Impact factor: 9.473

Review 9.  Cross-talk signaling in the trigeminal ganglion: role of neuropeptides and other mediators.

Authors:  Karl Messlinger; Louis K Balcziak; Andrew F Russo
Journal:  J Neural Transm (Vienna)       Date:  2020-02-22       Impact factor: 3.575

10.  Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system.

Authors:  Alejandro Labastida-Ramírez; Eloísa Rubio-Beltrán; Kristian A Haanes; Kayi Y Chan; Ingrid M Garrelds; Kirk W Johnson; Alexander H J Danser; Carlos M Villalón; Antoinette MaassenVanDenBrink
Journal:  Pain       Date:  2020-05       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.